Suzhou Zelgen Biopharmaceuticals Co (SHSE:688266) Beneish M-Score: -2.05 (As of Jul. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:688266 Suzhou Zelgen Biopharmaceuticals Co Ltd SHSE:688266
67 GF Score
Price ¥140.00
GF Value ¥216.30
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is Suzhou Zelgen Biopharmaceuticals Co Beneish M-Score?

Suzhou Zelgen Biopharmaceuticals Co SHSE:688266 -0.85% 67 Beneish M-Score is -2.05 as of Jul. 22, 2026. GuruFocus rates SHSE:688266 with a GF Score™ of 67/100 and a GF Value™ of ¥216.30 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 825 Biotechnology companies, Suzhou Zelgen Biopharmaceuticals Co ranks worse than 60.73% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.05 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Suzhou Zelgen Biopharmaceuticals Co's Beneish M-Score or its related term are showing as below:

SHSE:688266' s Beneish M-Score Range Over the Past 10 Years
Min: -2.8   Med: -2.36   Max: 5.16
Current: -2.05

During the past 10 years, the highest Beneish M-Score of Suzhou Zelgen Biopharmaceuticals Co was 5.16. The lowest was -2.80. And the median was -2.36.


Suzhou Zelgen Biopharmaceuticals Co Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Suzhou Zelgen Biopharmaceuticals Co's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Suzhou Zelgen Biopharmaceuticals Co Beneish M-Score Chart

Suzhou Zelgen Biopharmaceuticals Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.16 -2.65 -2.52 -2.64 -2.74

Suzhou Zelgen Biopharmaceuticals Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.48 -2.36 -2.55 -2.74 -2.05

SHSE:688266 vs VRTX, REGN, ALNY: Beneish M-Score Comparison

For the Biotechnology subindustry, Suzhou Zelgen Biopharmaceuticals Co's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Suzhou Zelgen Biopharmaceuticals Co Beneish M-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Suzhou Zelgen Biopharmaceuticals Co's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Suzhou Zelgen Biopharmaceuticals Co's Beneish M-Score falls into.


SHSE:688266
67GF Score
Suzhou Zelgen Biopharmaceuticals Co Ltd SHSE:688266
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Suzhou Zelgen Biopharmaceuticals Co Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Suzhou Zelgen Biopharmaceuticals Co for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.5221+0.528 * 0.9701+0.404 * 0.3892+0.892 * 2.6137+0.115 * 1
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.7873+4.679 * -0.085934-0.327 * 0.809
=-2.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was ¥201 Mil.
Revenue was 905.391 + 217.045 + 217.79 + 208.008 = ¥1,548 Mil.
Gross Profit was 878.354 + 196.356 + 199.665 + 188.655 = ¥1,463 Mil.
Total Current Assets was ¥3,159 Mil.
Total Assets was ¥3,688 Mil.
Property, Plant and Equipment(Net PPE) was ¥495 Mil.
Depreciation, Depletion and Amortization(DDA) was ¥0 Mil.
Selling, General, & Admin. Expense(SGA) was ¥380 Mil.
Total Current Liabilities was ¥1,339 Mil.
Long-Term Debt & Capital Lease Obligation was ¥92 Mil.
Net Income was 632.613 + -69.53 + -20.613 + -44.541 = ¥498 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = ¥0 Mil.
Cash Flow from Operations was 837.414 + -12.048 + 0.286 + -10.767 = ¥815 Mil.
Total Receivables was ¥147 Mil.
Revenue was 167.642 + 148.837 + 143.42 + 132.452 = ¥592 Mil.
Gross Profit was 148.174 + 138.87 + 133.892 + 122.106 = ¥543 Mil.
Total Current Assets was ¥2,497 Mil.
Total Assets was ¥2,918 Mil.
Property, Plant and Equipment(Net PPE) was ¥352 Mil.
Depreciation, Depletion and Amortization(DDA) was ¥0 Mil.
Selling, General, & Admin. Expense(SGA) was ¥185 Mil.
Total Current Liabilities was ¥1,325 Mil.
Long-Term Debt & Capital Lease Obligation was ¥73 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(201.109 / 1548.234) / (147.365 / 592.351)
=0.129896 / 0.24878
=0.5221

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(543.042 / 592.351) / (1463.03 / 1548.234)
=0.916757 / 0.944967
=0.9701

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (3158.916 + 495.199) / 3688.386) / (1 - (2496.56 + 351.608) / 2917.824)
=0.009292 / 0.023873
=0.3892

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=1548.234 / 592.351
=2.6137

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0 / (0 + 351.608)) / (0 / (0 + 495.199))
=0 / 0
=1

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(379.83 / 1548.234) / (184.574 / 592.351)
=0.245331 / 0.311596
=0.7873

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((91.512 + 1338.521) / 3688.386) / ((72.886 + 1325.482) / 2917.824)
=0.387712 / 0.47925
=0.809

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(497.929 - 0 - 814.885) / 3688.386
=-0.085934

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Suzhou Zelgen Biopharmaceuticals Co has a M-score of -2.05 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.05 mean?
Suzhou Zelgen Biopharmaceuticals Co (SHSE:688266) has a Beneish M-Score of -2.05 as of Jul. 22, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Suzhou Zelgen Biopharmaceuticals Co and its competitors. According to the industry distribution chart, Suzhou Zelgen Biopharmaceuticals Co ranks #501 out of 825 companies in the Biotechnology industry, placing it in the top 60.7%.
Is Suzhou Zelgen Biopharmaceuticals Co's Beneish M-Score too high?
Suzhou Zelgen Biopharmaceuticals Co's current Beneish M-Score is -2.05. Based on the distribution chart, Suzhou Zelgen Biopharmaceuticals Co ranks #501 out of 825 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Suzhou Zelgen Biopharmaceuticals Co has a GF Score™ of 67/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Suzhou Zelgen Biopharmaceuticals Co's Beneish M-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Suzhou Zelgen Biopharmaceuticals Co ranks #501 out of 825 companies for Beneish M-Score. This places Suzhou Zelgen Biopharmaceuticals Co in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Biotechnology company?
A good Beneish M-Score depends on the Biotechnology industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Suzhou Zelgen Biopharmaceuticals Co and its competitors. Suzhou Zelgen Biopharmaceuticals Co's current Beneish M-Score is -2.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Suzhou Zelgen Biopharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Suzhou Zelgen Biopharmaceuticals Co (SHSE:688266) is currently considered Significantly Undervalued. The stock's GF Value™ is ¥216.30, compared to a current price of ¥140.00 — trading 35.3% below its estimated fair value. The current Beneish M-Score is -2.05. Suzhou Zelgen Biopharmaceuticals Co's overall GF Score™ is 67/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Suzhou Zelgen Biopharmaceuticals Co (SHSE:688266), the current Beneish M-Score is -2.05 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Suzhou Zelgen Biopharmaceuticals Co (SHSE:688266) Overvalued in 2026?

Based on GuruFocus' analysis, Suzhou Zelgen Biopharmaceuticals Co stock appears to be undervalued. The current stock price of ¥140.00 is trading 35.3% below its estimated GF Value™ of ¥216.30. GuruFocus considers Suzhou Zelgen Biopharmaceuticals Co to be Significantly Undervalued.

Key valuation signals for SHSE:688266:

  • Beneish M-Score: -2.05
  • GF Value™: ¥216.30 vs. price of ¥140.00 (35.3% below fair value)
  • GF Score™: 67/100 with 4 warning signs

No single metric tells the full story. See the SHSE:688266 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Suzhou Zelgen Biopharmaceuticals Co Business Description

Address No.209 Chenfeng Road, Yushan Town, Jiangsu Province, Kunshan, CHN
Suzhou Zelgen Biopharmaceuticals Co Ltd is engaged in research and development of new chemical and biological drugs for various therapeutic areas, including tumors, bleeding and blood diseases, and hepatobiliary diseases.
67GF Score

Get the complete analysis for SHSE:688266

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥140.00
Price
¥216.30
GF Value